Russell,Stephen J

Institution: Mayo Clinic, USA

Research Interests: Virus, Tumor, Viruses, Cancer, Mice, Cells, Gene, Treatment, Cell, Stomatitis, Vesicular Stomatitis, Sodium, Human, Measles, Patients, Tumors, Administration, Measles Virus, Genome, Multiple Myeloma

Publications
Grants

Information and abstracts for author publications
Published Date	Impact	Publication
03/19/2012	9.6	Leukemia Curative one-shot systemic virotherapy in murine myeloma.	Abstract
03/19/2010	9.1	PLoS pathogens MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference.	Abstract
10/02/2012	8.2	Cell research A new paradigm in viral resistance.	Abstract
12/28/2012	8.1	Diabetes care A comparative effectiveness analysis of three continuous glucose monitors.	Abstract
01/26/2010	7.9	Cancer research Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.	Abstract
04/19/2011	6.9	Molecular therapy : the journal of the American Society of Gene Therapy Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid.	Abstract
12/23/2008	6.9	Molecular therapy : the journal of the American Society of Gene Therapy MicroRNAs and the regulation of vector tropism.	Abstract
01/02/2013	5.4	Journal of virology Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites.	Abstract
01/16/2013	5.4	Journal of virology PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice.	Abstract
11/11/2009	5.4	Journal of virology Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting.	Abstract
10/02/2013	5.4	Journal of virology Characteristics of oncolytic vesicular stomatitis virus displaying tumor-targeting ligands.	Abstract
07/01/2009	4.7	American journal of hematology Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.	Abstract
11/22/2010	4.3	Expert review of vaccines Use of attenuated paramyxoviruses for cancer therapy.	Abstract
10/15/2013	4.3	Expert review of vaccines Oncolytic vaccines.	Abstract
01/11/2012	4.2	Human gene therapy Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy.	Abstract
04/05/2012	3.7	Gene therapy Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses.	Abstract
08/05/2009	3.5	Expert opinion on biological therapy Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways.	Abstract
09/22/2013	2.9	Experimental hematology Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo.	Abstract
12/22/2008	2.9	AJR. American journal of roentgenology Quantitative molecular imaging of viral therapy for pancreatic cancer using an engineered measles virus expressing the sodium-iodide symporter reporter gene.	Abstract
10/19/2009	2.8	The Medical journal of Australia A consensus statement on the management of pregnancy and delivery in women who are carriers of or have bleeding disorders.	Abstract
04/09/2010	2.8	Cancer gene therapy Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy.	Abstract
04/20/2012	2.8	Cancer gene therapy Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.	Abstract
11/01/2013	2.8	Cancer gene therapy Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV.	Abstract
07/19/2013	2.8	Cancer gene therapy HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy.	Abstract
02/25/2009	2.5	The journal of gene medicine Concordant activity of transgene expression cassettes inserted into E1, E3 and E4 cloning sites in the adenovirus genome.	Abstract
11/20/2012	2.4	Clinical trials (London, England) Obtaining surrogate consent for a minimal-risk research study in the intensive care unit setting.	Abstract
04/24/2012	2.1	Journal of biomaterials applications Technique for internal channelling of hydroentangled nonwoven scaffolds to enhance cell penetration.	Abstract

Grants Recieved by this author
Budget Start	Budget End	Grant Type	Project Cost	Project Title
7/18/2012	6/30/2014	NIH R01: Research Project	$996,912	Measles Virotherapy for Multiple Myeloma
4/08/2008	1/31/2013	NIH R01: Research Project	$1,621,995	Radiovirotherapy for Multiple Myeloma
4/11/2008	1/31/2013	NIH R01: Research Project	$2,473,836	Antibody Neutralization of Therapeutic Viruses
9/22/2010	8/31/2011	NIH R44: Small Business Innovation Research Grants (SBIR) - Phase II	$147,909	Virotherapy for Squamous Cell Carcinoma of the Head and Neck